Concepedia

Publication | Closed Access

Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway

DOI

78

Citations

38

References

2013

Year

Lana McClements, Anita Yakkundi, Angelos Papaspyropoulos, Hannah Harrison, Matthew P. Ablett, Puthen V. Jithesh, Hayley D. McKeen, R. Avery Bennett, Christopher Donley, Adrien Kissenpfennig,
Clinical Cancer Research

Abstract

AD-01 has dual antiangiogenic and anti-BCSC activity, which will be advantageous as this agent enters clinical trial.

References

YearCitations

Page 1